TY - JOUR T1 - Distinct blood protein profiles associated with the risk of short-term and mid/long-term clinical relapse in patients with Crohn's disease stopping infliximab: when the remission state hides different types of residual disease activity JF - Gut JO - Gut SP - 443 LP - 450 DO - 10.1136/gutjnl-2022-327321 VL - 72 IS - 3 AU - Nicolas Pierre AU - Vân Anh Huynh-Thu AU - Thomas Marichal AU - Matthieu Allez AU - Yoram Bouhnik AU - David Laharie AU - Arnaud Bourreille AU - Jean-Frédéric Colombel AU - Marie-Alice Meuwis AU - Edouard Louis A2 - , Y1 - 2023/03/01 UR - //www.marcconsult.com/content/72/3/443.abstract N2 - Objective Despite being in sustained and stable remission, patients with Crohn's disease (CD) stopping anti-tumour necrosis factor α (TNFα) show a high rate of relapse (~50% within 2 years).需要非渗透式描述这些病人的生物剖面图,以便更好地指导反TNFAT提取决策。前文显示,基于时间分层复发用于描述复发者的独特生物特征(短期复发者:<6个月对中长复发者:>6个月)。蛋白质水平和时间间复发关联由不可变Cox模型确定。 中长期复发风险与高血清蛋白具体相关,主要以淋巴细胞表示(LAG3、SH2B3、SIT1!HR:2.2-4.5p<0.05低血清级抗炎效果器(IL-10HSD11B1HR:0.2-0.3手机接合蛋白质CDSNCNP2CXADRITGA110.4p < 0.05短期临床复发风险与高血清亲炎效果器相关联(IL-6,IL12RB1HR:3.5-3.6低或高血清蛋白主要表现为抗原显示细胞(CLEC4A、CLEC4C、CLEC7A、LAMP30.4比4.确定异性血蛋白剖剖面图与CD停用fliximab的病人短期和中长期临床复发风险相关研究结果预开发非入侵生物标志指导反TNFAT提取决定.Data可应合理请求获取支持报告结果的数据(识别个人参与数据和PEA原始数据)可应请求分享给相关作者辅助表提供所有处理数据ER-